Download PDF
1
/
Pages
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study
Ignacio Marín-Jiménez; Manuel Barreiro-de Acosta; María Esteve; Luisa Castro-Laria; Santiago García-López; Daniel Ceballos; Ana Echarri; María Dolores Martín-Arranz; David Busquets; Jordina Llaó; Mercè Navarro-Llavat; José María Huguet; Federico Argüelles-Arias; Raquel Vicente; José Miguel Boudet; Gema Díaz; Ana M. Sánchez-Migallón; Francesc Casellas;
Gastroenterol Hepatol. 2022;45:165-76
De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice
Alex Arenas; María José Moreta; Ingrid Ordás; Agnès Fernández-Clotet; Berta Caballol; Marta Gallego; Alejandro Vara; Rebeca Barastegui; Angel Giner; Cristina Prieto; Maria Carme Masamunt; Roberto Candia; Elena Ricart;
Gastroenterol Hepatol. 2024;47:673-82
Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease
Lidia Serrano Díaz; Carles Iniesta Navalón; Rosa Gómez Espín; Isabel Nicolás de Prado; Lorena Rentero Redondo;
Gastroenterol Hepatol. 2023;46:504-11